A comparison of a sucrose-based solution with other preservation media for cold storage of isolated hepatocytes

Recent Developments in Cell Shipping Methods

As opposed to remarkable advances in the cell therapy industry, researches reveal inexplicable difficulties associated with preserving and post-thawing cell death. Post cryopreservation apoptosis is a common occurrence that has attracted the attention of scientists to use apoptosis inhibitors. Transporting cells without compromising their survival and function is crucial for any experimental cell-based therapy. Preservation of cells allows the safe transportation of cells between distances and improves quality control testing in clinical and research applications. The vitality of transported cells is used to evaluate the efficacy of transportation strategies. For many decades, the conventional global methods of cell transfer were not only expensive but also challenging and had adverse effects. The first determination of some projects is optimizing cell survival after cryopreservation. The new generation of cryopreservation science wishes to find appropriate and alternative methods for cell transportation to ship viable cells at an ambient temperature without dry ice or in media-filled flasks. The diversity of cell therapies demands new cell shipping methodologies and cryoprotectants. In this review, we tried to summarize novel improved cryopreservation methods and alternatives to cryopreservation with safe and viable cell shipping at ambient temperature, including dry preservation, hypothermic preservation, gel-based methods, encapsulation methods, fibrin microbeads, and osmolyte solution compositions. This article is protected by copyright. All rights reserved.

Clinically Relevant Solution for the Hypothermic Storage and Transportation of Human Multipotent Mesenchymal Stromal Cells

The wide use of human multipotent mesenchymal stromal cells (MSCs) in clinical trials requires a full-scale safety and identity evaluation of the cellular product and subsequent transportation between research/medical centres. This necessitates the prolonged hypothermic storage of cells prior to application. The development of new, nontoxic, and efficient media, providing high viability and well-preserved therapeutic properties of MSCs during hypothermic storage, is highly relevant for a successful clinical outcome. In this study, a simple and effective trehalose-based solution was developed for the hypothermic storage of human bone marrow MSC suspensions for further clinical applications. Human bone marrow MSCs were stored at 4°C for 24, 48, and 72 hrs in the developed buffered trehalose solution and compared to several research and clinical grade media: Plasma-Lyte® 148, HypoThermosol® FRS, and Ringer's solution. After the storage, the preservation of viability, identity, and therapeutically associated properties of MSCs were assessed. The hypothermic storage of MSCs in the new buffered trehalose solution provided significantly higher MSC recovery rates and ability of cells for attachment and further proliferation, compared to Plasma-Lyte® 148 and Ringer's solution, and was comparable to research-grade HypoThermosol® FRS. There were no differences in the immunophenotype, osteogenic, and adipogenic differentiation and the immunomodulatory properties of MSCs after 72 hrs of cold storage in these solutions. The obtained results together with the confirmed therapeutic properties of trehalose previously described provide sufficient evidence that the developed trehalose medium can be applied as a low-cost and efficient solution for the hypothermic storage of MSC suspensions, with a high potential for translation into clinical practice.

Hypothermic storage of hepatocytes used for bioartificial liver support system: current status and recent advances

The problem that high-quality hepatocytes are difficult to obtain restricts the use of bioartificial liver support system (BLASS) in clinical practice. Finding an effective way to preserve hepatocytes and constructing a "ready-to-use" hepatocyte bank would efficiently promote the development of the BLASS. Nowadays, the methods for hypothermic storage of hepatocytes could be classified into two types: conventional hypothermic storage at 4 °C or subzero nonfreezing storage, and cryopreservation at -80 °C or -196 °C. Each type of hypothermic storage method has its advantages and disadvantages. Many factors may affect the effect of hypothermic storage (cryopreservation), such as storage solution and cryoprotective agent. Although the precise mechanism underlying the death of hepatocytes during hypothermic storage is not well understood, numerous studies have indicated that apoptosis plays an important role in hypothermic storage injury.

Subzero nonfreezing storage of C3A hepatocytes for use in bioartificial liver support systems

AIM: To investigate whether subzero nonfreezing storage (-0.8 °C) is superior to conventional cold storage in preservation of C3A hepatocytes for use in bioartificial liver support systems.

METHODS: C3A hepatocytes suspended in University of Wisconsin (UW) solution were divided into three groups: subzero nonfreezing group (-0.8 °C), zero nonfreezing group (0 °C) and control group (4 °C). After 24, 48 and 72 hours of hypothermic storage, cell viability and apoptosis were detected by flow cytometry; intracellular adenosine triphosphate (ATP) content, lactate dehydrogenase (LDH) release, lactic acid production, urea synthesis and albumin secretion were determined; and cell morphological changes were observed.

RESULTS: Compared to the zero nonfreezing group and the control group, after 72 hours of hypothermic storage, the percentage of viable C3A hepatocytes was significantly higher (86.49% ± 2.80% vs 81.50% ± 2.83% and 77.83% ± 3.40%, respectively; both P < 0.05), and cell apoptosis rate was significantly lower (1.26% ± 0.84% vs 5.34% ± 1.20% and 9.16% ± 1.99%, respectively; both P < 0.05) in the subzero nonfreezing group. Lactic acid and LDH production was more significantly suppressed (lactic acid: 10.38 μg/10⁶ cells ± 1.40 μg/10⁶ cells vs 12.02 μg/10⁶ cells ± 1.64 μg/106 cells and 17.41 μg/10⁶ cells ± 2.40 μg/10⁶ cells; LDH: 80.10 U/L ± 11.10 U/L vs 120.04 U/L ± 14.32 U/L and 148.98 U/L ± 15.37 U/L, respectively; all P < 0.05), and the ability of hepatocytes to synthesize urea and secrete albumin was better maintained in the subzero nonfreezing group (both P < 0.05). Moreover, cells in the subzero nonfreezing storage group had lower death rate and better cellular morphology. A burr-like structure around the cell membrane and an intracellular vacuole-like structure were found in cells in the zero nonfreezing group and the control group, but not in the subzero nonfreezing group.

CONCLUSION: Subzero nonfreezing storage (-0.8 °C) of hepatocytes to construct a "ready-to-use" hepatocyte bank like the "blood bank" will efficiently promote the development of bioartificial liver support systems.

Hypothermic storage of isolated human hepatocytes: a comparison between University of Wisconsin solution and a hypothermosol platform

Until now little is known about the functional integrity of human hepatocytes after hypothermic storage. In order to address this limitation, we evaluated several commercially available hypothermic preservation media for their abilities to protect freshly isolated hepatocytes during prolonged cold storage. Human hepatocytes were isolated from non-transplantable/rejected donor livers and resuspended in ice-cold University of Wisconsin solution (UW), HypoThermosol-Base (HTS-Base), or HypoThermosol-FRS (HTS-FRS) with or without the addition of fetal bovine serum. Cells were stored at 4 degrees C for 24-72 h, and evaluated for hepatocyte viability (trypan blue exclusion, or labeling with fluorochromes), cell attachment, and function. The energy status of hepatocytes was evaluated by measurement of intracellular adenosine 5'-triphosphate. To determine whether the test cells expressed metabolic functions of freshly isolated cells, the activities of major phase I (cytochromes P450, FMO) and phase II (UGT, ST) drug-metabolizing enzymes were examined. Although hepatocytes are shown to be satisfactory after 24 h storage in all of the tested solutions, the cell viability, energy status, and xenobiotic metabolism following cold preservation in HTS-FRS was consistently and, in some cases, markedly higher when compared with other systems. The same metabolites for each of the tested substrates were detected in all groups of cells. Moreover, the use of HTS-FRS eliminates the need for serum in preservation solutions. HTS-FRS represents an improved solution compared to HTS-Base and UW for extending the shipping/storage time of human hepatocytes.

Heat preconditioning ameliorates hepatocyte viability after cold preservation and rewarming, and modulates its immunoactivity

BACKGROUND

Heat preconditioning significantly preserved liver graft function after cold preservation in animal experimental model. The elevation of heat shock protein 70 (HSP70) was claimed to play a critical role in protecting grafts against cold preservation-induced hepatocyte apoptosis. However, little is known about whether HSP70 also plays an immunomodulatory role in cold preserved cells. This study aimed at investigating the relationship between HSP70 protein and the immunoactivity in response to lipopolysaccharide (LPS) stimulation.

METHODS AND RESULTS

A normal rat hepatocyte cell line was preserved with University of Wisconsin (UW) solution, Ringer's lactate solution (RL), and phosphate-buffered saline (PBS) at 4 degrees C. No significant morphological alteration was noted in UW-preserved cells after 24 h through phase-contrast microscopic observation and fluorescent viability stain. Western blotting showed a two-fold increase in the ratio of HSP70/Bax proteins in cells after 24 h of UW preservation. Heat preconditioning significantly enhanced the recovery of lactate dehydrogenase (LDH) activity in both RL- and UW-preserved cells that were stored for a period of 12 h or less. Moreover, heat preconditioning promoted HSP70 and NF-kappaB p50 nuclear translocation and suppressed the LPS-induced nuclear p50 accumulation in cells before UW preservation. Immunofluorescent stain revealed that the LPS-induced p50 protein redistribution to nuclear membrane might contribute to NF-kappaB activation, while heat preconditioning and UW cold preservation completely abrogated the p50 intranuclear redistribution. Thus NF-kappaB p50 might be responsible for the endotoxin tolerance induction.

CONCLUSIONS

These findings strongly suggest that heat preconditioning not only preserves hepatocyte viability after cold preservation and rewarming, but also ameliorates its immunoactivity.

Respiratory activity of isolated rat hepatocytes following cold storage and subsequent rewarming: a comparison of sucrose-based and University of Wisconsin solutions

Investigations were carried out on the respiratory function of isolated rat hepatocytes after cold storage alone for periods up to 48 h in either sucrose-based solution (SBS) or University of Wisconsin (UW) solution and after subsequent normothermic preincubation. In both SBS and UW, cold storage for 24 h depressed respiratory function (to 21 +/- 3 and 23 +/- 3 nmol O(2)/min/10(6) cells, respectively) compared to control cell values (31 +/- 3 and 33 +/- 5 nmol O(2)/min/10(6) cells; P < 0.01 in each case). However, normothermic preincubation for 60 min returned respiratory activity to control values (for SBS and UW storage: 41 +/- 6 and 40 +/- 5 nmol O(2)/min/10(6) cells; for control cells: 43 +/- 5 and 46 +/- 6 nmol O(2)/min/10(6) cells). Storage for 48 h in both SBS and UW allowed further depression of respiratory activity, with no recovery after preincubation. Stimulation of respiration by succinate in hepatocytes stored for longer periods was suggestive of increased membrane permeability. Both SBS and UW are effective storage solutions for isolated hepatocytes for up to 24 h as judged by aerobic metabolism, but significant damage was expressed in both solutions when preservation was extended.